Sandra N. Webb
Directeur/Bestuurslid bij Ground Zero Pharmaceuticals Pty Ltd.
Profiel
Sandra N.
Webb is currently a Director at Ground Zero Pharmaceuticals Pty Ltd.
She was previously a Director at CSL Innovation Pty Ltd.
and a Director at AusBiotech Ltd.
Additionally, she served as an Independent Non-Executive Director at Avecho Biotechnology Ltd.
from 2010 to 2014.
Actieve functies van Sandra N. Webb
| Bedrijven | Functie | Begin |
|---|---|---|
| Ground Zero Pharmaceuticals Pty Ltd. | Directeur/Bestuurslid | 09-12-2010 |
Eerdere bekende functies van Sandra N. Webb
| Bedrijven | Functie | Einde |
|---|---|---|
| AVECHO BIOTECHNOLOGY LIMITED | Directeur/Bestuurslid | 03-03-2014 |
| ZENYTH THERAPEUTICS LIMITED | Directeur/Bestuurslid | - |
AusBiotech Ltd.
 AusBiotech Ltd. Miscellaneous Commercial ServicesCommercial Services AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AVECHO BIOTECHNOLOGY LIMITED | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
| Ground Zero Pharmaceuticals Pty Ltd. | |
AusBiotech Ltd.
AusBiotech Ltd. Miscellaneous Commercial ServicesCommercial Services AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008. | Commercial Services |
CSL Innovation Pty Ltd.
 CSL Innovation Pty Ltd. Pharmaceuticals: MajorHealth Technology CSL Innovation Pty Ltd. develops pharmaceutical products. The firm also develops human antibody inhibitors of the granulocyte-macrophage colony stimulating factor receptor alpha subunit, GM-CSFRa, for potential therapeutic use in inflammatory diseases. The company was founded in 1986 and is headquartered in Richmond, Australia. | Health Technology |